Kelli Solly

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

Total Citations

H-Index

About

Kelli Solly is a distinguished researcher whose work has significantly advanced the field of high-throughput screening (HTS) and cell-based assay development. Her primary research focuses on innovative methodologies for improving the efficiency, consistency, and scalability of cellular assays used in drug discovery. Solly’s most influential contribution is her pioneering work on division arrest technology, detailed in her highly cited 2005 paper (33 citations), which demonstrated how to create stable, consistent cell populations for HTS—a critical breakthrough that addressed the logistical challenge of supplying live cells with uniform responses over extended screening periods. She further expanded the field’s capabilities with her 2011 study on a miniaturized homogenous assay for mitochondrial membrane potential (6 citations), a tool vital for investigating mitochondrial dysfunction in diseases like Parkinson’s, Alzheimer’s, and type 2 diabetes. By enabling more reliable, miniaturized, and physiologically relevant cell-based assays, Solly’s work has directly impacted the efficiency of drug discovery pipelines and deepened our understanding of mitochondrial roles in disease pathology.